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Abstract
Background Lubiprostone is a ClC-2 chloride channel
activator approved for the treatment of chronic idiopathic
constipation (CIC) and opioid-induced constipation (OIC)
in adults and irritable bowel syndrome with constipation
(IBS-C) in women. Lubiprostone is generally well toler-
ated, with nausea being the most common adverse event.
Aims To characterize nausea with lubiprostone using
pooled results from clinical studies in patients with CIC,
OIC, or IBS-C.
Methods Data from three 3- and 4-week placebo-con-
trolled studies and three long-term open-label studies were
pooled for the CIC analysis. The OIC and IBS-C analyses
each used pooled data from three 12-week placebo-
controlled studies and one 36-week open-label extension
study.
Results The populations included the following numbers
of patients: CIC, 316 (placebo) and 1113 (lubiprostone 24
mcg twice daily [BID]); OIC, 652 (placebo) and 889 (lu-
biprostone 24 mcg BID); and IBS-C, 435 (placebo) and
1011 (lubiprostone 8 mcg BID). The incidence of nausea in
lubiprostone-treated patients ranged from 11.4 to 31.1%,
with the highest incidence in patients with CIC. Among
patients with any nausea, most reported only mild or
moderate severity (96.5–99.1% across indications) and
only one event (83.6–88.7%); most events occurred within
the first 5 days of treatment.
Conclusions Nausea was the most common adverse event
following the treatment with lubiprostone. Event rates
varied by indication and dose, and the majority of nausea
adverse events were mild to moderate in severity. Nausea
events predominantly occurred early in the treatment per-
iod in all of the pooled study populations.
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Introduction
Lubiprostone is an orally active ClC-2 chloride channel
activator indicated for the treatment of chronic idiopathic
constipation (CIC) in adults (24 mcg twice daily [BID]),
opioid-induced constipation (OIC) in adults with chronic
non-cancer pain (24 mcg BID), and irritable bowel syn-
drome with constipation (IBS-C) in women C18 years old
(8 mcg BID) [1, 2]. Structurally, lubiprostone is a prostone;
mechanistically, it acts locally within the gastrointestinal
tract to promote intestinal secretion by activating ClC-2
chloride channels, resulting in the addition of fluid to stool
and more rapid transit time [2]. In healthy adults,
lubiprostone slows gastric emptying and decreases small
bowel transit time [3]. The overall safety profile of
lubiprostone is consistent among clinical studies; lubipro-
stone is generally well tolerated, with most adverse events
(AEs) reported as mild or moderate in severity [4–6].
Nausea was generally the most frequently reported AE in
individual studies of patients receiving lubiprostone
[5–16]. The clinical profiles of patients who are more likely
to experience nausea with lubiprostone and the character-
istics of lubiprostone-related nausea have not been well
delineated.
The purpose of this article is to analyze the incidences of
nausea in pivotal and long-term open-label safety studies of
lubiprostone in patients with CIC, OIC, and IBS-C. This
comprehensive characterization of nausea may serve to
identify patients who are at greater risk of experiencing
nausea after treatment with lubiprostone, inform clinicians
about the expected timing and severity of nausea when it
does occur, and provide data on the likelihood that treat-
ment may continue following reduction or temporary
interruption of dosing.
Methods
Included Studies
In these post hoc analyses, data from the clinical devel-
opment program for each indication (Table 1; Figure S1)
were combined. Only data for patients assigned to receive
placebo or the currently approved doses of lubiprostone
were included in the present analyses (Figure S1). All
randomized controlled trials (RCTs) analyzed in these post
hoc analyses fulfilled criteria on the Jadad scale assessing
the quality of studies [17]. For CIC treatment, data were
from six studies. Three of the CIC studies were random-
ized, double-blind, placebo-controlled trials lasting
3–4 weeks [5, 7, 8], and two were open-label 24- and
48-week extension studies [9, 10]. The sixth CIC study
included 4 weeks of active treatment, a 3-week randomized
withdrawal, and a 48-week open-label period [6].
Lubiprostone was administered at 24 mcg BID in all of the
studies except the 3-week study, in which patients were
treated with 24, 48, or 72 mcg (total dose). For OIC
treatment, data were from three randomized, double-blind,
12-week, placebo-controlled studies (registered on Clini-
calTrials.gov as NCT01298219 [11], NCT00595946, and
NCT00597428) and one 36-week open-label extension
study (NCT00620061) [16]. In all of these OIC studies,
patients were treated with 24 mcg BID lubiprostone. For
IBS-C treatment, data were from three randomized, dou-
ble-blind, 12-week, placebo-controlled studies
(NCT00380250 and NCT00399542 [13], and a third study
[14]) and one 36-week open-label extension study (con-
tinuation of NCT00380250 and NCT00399542) [15]. In
one of the IBS-C studies [14], patients were treated orally
with 8, 16, or 24 mcg BID lubiprostone; the treatment dose
was 8 mcg BID in all of the other studies. In all of the
studies, patients were instructed to take their medications
with the morning and evening meals.
Patient Criteria
Patient criteria specific to the clinical studies have been
described previously [5–16]. In all of the lubiprostone
development programs (CIC, OIC, and IBS-C), patients
were required to be C18 years of age and to meet criteria
with respect to the maximum weekly frequency of spon-
taneous bowel movements (SBMs) and symptoms of con-
stipation. ‘‘Spontaneous’’ was defined as a bowel
movement occurring without the use of laxatives or stool
softeners within the prior 24-h period. Signs and symptoms
of constipation comprised C1 of the following, which had
to be present for C25% of the SBMs during each week of
the baseline washout period: hard or very hard stools,
sensation of incomplete evacuation (for CIC and OIC
studies), and/or moderate to very severe straining associ-
ated with the SBMs. Exclusion criteria included docu-
mented mechanical obstruction; organic bowel disorders;
constipation secondary to a documented cause; clinically
significant cardiovascular, liver, lung, neurologic, or psy-
chiatric disorder; or significant laboratory abnormalities.
Patients in the CIC studies had a documented history of
constipation and, during the baseline washout period, \3
SBMs per week and signs and symptoms of constipation.
Patients in the OIC studies had chronic non-cancer-related
pain being treated consistently with an opioid for C30 days
before the baseline washout and that would require
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continued opioid treatment during the study. Patients had
\3 SBMs per week and signs and symptoms of constipa-
tion during the baseline washout period. Patients with a
history of chronic constipation (C90 days) could be
included if they experienced an exacerbation in constipa-
tion after the initiation of opioid therapy. Patients receiving
opioid treatment for cancer-related pain, abdominal pain,
or scleroderma, or for the management of drug addiction
were excluded. ‘‘Study 1’’ (NCT01298219) in patients with
OIC excluded patients who were receiving opioids of the
diphenylheptane class (e.g., methadone). Specific inclusion
criteria for IBS-C studies were that patients meet Rome II
Table 1 Study design summary
Study Design Treatment (n=)* Duration of treatment
(week)
Dosing instructions
CIC
RTU0211SC9921 Double-blind
Randomized
Placebo (33)
LUB 24 mcg (29)
LUB 48 mcg (32)
LUB 72 mcg (33)
3 Before meals, w/C8 oz of
water
RTU0211SC0131 Double-blind
Randomized
Placebo (122)
LUB 24 mcg BID (120)
4 w/food and C8 oz of water
SPI0211SC0232 Double-blind
Randomized
Placebo (118)
LUB 24 mcg BID (119)
4 w/food and C 8 oz of water
RTU0211SC01S1 Open-label LUB 24 mcg BID (306) 24 w/food and C8 oz of water
RTU0211SC01S2
(period 1)
Active treatment
Randomized
withdrawal
LUB 24 mcg BID (128)
Placebo (42)
LUB 24 mcg BID (45)
4
3
w/food and C8 oz of water
RTU0211SC01S2
(period 2)
Open-label LUB 24 mcg BID (248) 48 w/food and C 8 oz of water
SPI0211SC02S3 Open-label LUB 24 mcg BID (324) 48 w/food and C8 oz of water
OIC
OBD-1033 Double-blind
Randomized
Placebo (220)
LUB 24 mcg BID (219)
12 w/food and C8 oz of water
OBD-631 Double-blind
Randomized
Placebo (217)
LUB 24 mcg BID (222)
12 w/food and C8 oz of water
OBD-632 Double-blind
Randomized
Placebo (213)
LUB 24 mcg BID (224)
12 w/food and C8 oz of water
OBD-06S1 Open-label LUB 24 mcg BID as needed
(439)
36 w/food
IBS-C
SPI/0211SIB-0221 Double-blind
Randomized
Placebo (48)
LUB 8 mcg BID (52)
LUB 16 mcg BID (49)
LUB 24 mcg BID (45)
12 w/food and C 8 oz of water
SPI/0211SIB-0431 Double-blind
Randomized
Placebo (193)
LUB 8 mcg BID (395)
12 (double-blind)
4 (randomized
withdrawal)a
w/food and C 8 oz of water
SPI/0211SIB-0432 Double-blind
Randomized
Placebo (194)
LUB 8 mcg BID (385)
12 w/food and C8 oz of water
SPI/0211SIB-05S1 Open-label LUB 8 mcg BID (520) 36 w/food and C8 oz of water
BID twice daily, CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, LUB lubiprostone, OIC opioid-induced
constipation
* Number of patients treated
a 139/193 placebo/placebo patients, 143/146 lubiprostone/placebo patients, and 146/151 lubiprostone/lubiprostone patients completed the
randomized withdrawal phase of this study
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Diagnostic Criteria for IBS assessed using the Rome II
Modular Questionnaire Criteria for IBS, have abdominal
discomfort/pain of at least mild severity, and experience
any two of the following:\3 SBMs per week C25% of the
time, C25% of SBMs associated with moderate or greater
straining, and C25% of SBMs associated with hard or very
hard stool consistency. For two of the studies, patients with
no SBMs during the baseline period did not have to meet
the straining or stool consistency criteria. Patients were
excluded from the IBS-C studies if they had diarrhea-pre-
dominant or alternating IBS, certain gastrointestinal or
abdominal surgeries, known or suspected organic disorders
of the small or large bowel, mechanical bowel obstruction
or pseudo-obstruction, significant unexplained weight loss,
unexplained rectal bleeding, and/or a diagnosis of consti-
pation other than IBS.
Assessments
Adverse events were noted and recorded at each study visit.
Nausea was considered a treatment-emergent AE if it
occurred after the initiation of treatment in patients without
nausea at baseline or if it was present at baseline and
subsequently worsened. The incidence, severity (mild,
moderate, and severe), and duration of treatment-emergent
AEs of nausea were categorized, as well as whether the
events of nausea were associated with study discontinua-
tion. The prebaseline nausea profile for patients in each of
the three indications was determined by medical history
and use of concomitant medications.
Statistical Analysis
Patients who entered the treatment period of a specific
study and received C1 dose of study medication were
included in the analyzed study population. Data were
pooled in two ways: data from RCTs only and ‘‘all trials.’’
Only patients who received lubiprostone were included in
the ‘‘all trials’’ analyses, because comparisons between
placebo and active treatment for ‘‘all trials’’ would be
inappropriate due to the substantially shorter exposure to
placebo compared with lubiprostone administered in open-
label extension studies. The incidence of nausea was
summarized descriptively, and differences between the
placebo and lubiprostone groups were determined by the
Fisher’s exact test for the RCT analyses only. A Cox
proportional hazards regression model was used for anal-
ysis of incidence rates for the time to the first occurrence of
nausea in RCTs for each indication. Categorical variables
analyzed for their effects on the Cox proportional hazard
ratios included treatment (active vs placebo), age (C65 vs
\65 years), and sex. Kaplan–Meier analysis was used to
evaluate the cumulative occurrence of nausea AEs over
time. Conditions that could predispose patients to nausea
[18] were coded using standard preferred terms and used to
search patient medical history.
Results
Baseline Characteristics of Patient Populations
A summary of analyzed populations is listed in Table 2.
The RCT CIC study population consisted of 240 patients
who received placebo and 239 who received lubiprostone
(24 mcg BID); for OIC, 652 and 663 patients, respectively,
received those treatments. For IBS-C, the 832 patients in
the lubiprostone group received an 8-mcg BID dose and
435 received placebo. The ‘‘all trials’’ populations con-
sisted of 1113 patients with CIC, 889 with OIC, and 1011
with IBS-C. Most patients in each clinical development
program were women.
For each indication, the percentages of patients in RCTs
reporting nausea at baseline or who had received treatment
for nausea before randomization were statistically similar
between patients who received placebo and lubiprostone.
However, patients with OIC had a higher incidence of
pretreatment nausea than those with CIC or IBS-C
(Table 2).
Nausea Incidences During Treatment
The crude incidence of treatment-emergent nausea in the
RCT populations was significantly higher in patients who
received lubiprostone (24 mcg BID for CIC and OIC; 8
mcg BID for IBS-C) compared with placebo for each
indication (CIC, 29.3 vs 6.3%, respectively; OIC, 13.4 vs
6.4%; IBS-C, 10.9 vs 6.4%; Table 2). The crude incidences
of nausea in the RCT and ‘‘all trials’’ lubiprostone-treated
patients were similar within each indication (Table 2).
For CIC analysis, the percentages of patients in RCTs
reporting mild, moderate, and severe nausea were signifi-
cantly higher with lubiprostone (24 mcg BID) than placebo
(19.2 vs 3.3%, 7.9 vs 2.9%, and 2.1 vs 0%, respectively;
Table 2). For the OIC analysis, the percentages of patients
in RCTs reporting mild (8.0 vs 3.7%) and moderate (4.4 vs
1.7%), but not severe (1.1 vs 1.1%) nausea, were signifi-
cantly higher for lubiprostone (24 mcg BID) compared
with placebo. For IBS-C analysis, the percentage of
patients in RCTs reporting moderate nausea was signifi-
cantly higher with lubiprostone (8 mcg BID) than placebo
(4.0 vs 1.4%), but the percentages of patients reporting
mild or severe nausea were similar (6.4 vs 4.8% and 0.6 vs
0.2%, respectively). In the ‘‘all trials’’ CIC population, who
were treated with lubiprostone for longer periods, inci-
dences of moderate and severe nausea were slightly higher
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than observed for RCTs. Similar incidences of mild,
moderate, and severe nausea were observed in the
lubiprostone-treated ‘‘all trials’’ OIC population compared
with the RCT population. The lubiprostone-treated ‘‘all
trials’’ IBS-C population reported similar nausea rates by
severity compared with the RCT population.
The percentage of patients discontinuing treatment
owing to nausea in RCTs was low but significantly greater
Table 2 Patient background and summary of nausea incidence by indication
CIC OIC IBS-C
Placebo Lubiprostone
24 mcg BID
Placebo Lubiprostone
24 mcg BID
Placebo Lubiprostone
8 mcg BID
n = 240 n = 239 n = 652 n = 663 n = 435 n = 832
Randomized controlled trials
Sex, n (%)
Male 25 (10.4) 28 (11.7) 244 (37.4) 247 (37.3) 31 (7.1) 75 (9.0)
Female 215 (89.6) 211 (88.3) 408 (62.6) 416 (62.7) 404 (92.9) 757 (91.0)
Exposure to lubiprostone,
median (range), mcg/day
0 46.3 (18.0–51.4) 0 43.3 (2.0–129.6) 0 14.18 (0–50.5)
Pretreatment nausea, n (%)
Medical history of nausea 8 (3.3) 10 (4.2) 60 (9.2) 56 (8.4) 8 (1.8) 26 (3.1)
Prior treatment for nausea 1 (0.4) 1 (0.4) 16 (2.5) 21 (3.2) 3 (0.7) 7 (0.8)
Treatment-emergent nausea, n (%)
Crude incidence 15 (6.3) 70 (29.3)* 42 (6.4) 89 (13.4)* 28 (6.4) 91 (10.9)
Milda 8 (3.3) 46 (19.2)* 24 (3.7) 53 (8.0)* 21 (4.8) 53 (6.4)
Moderatea 7 (2.9) 19 (7.9)§ 11 (1.7) 29 (4.4) 6 (1.4) 33 (4.0)§
Severea 0 5 (2.1)§ 7 (1.1) 7 (1.1) 1 (0.2) 5 (0.6)
Leading to discontinuation 0 12 (5.0)* 0 17 (2.6)* 3 (0.7) 10 (1.2)
CIC OIC IBS-C
Lubiprostone 24 mcg BID Lubiprostone 24 mcg BID Lubiprostone 8 mcg BID
n = 1113 n = 889 n = 1011
All trials
Sex, n (%)
Male 146 (13.1) 333 (37.5) 89 (8.8)
Female 967 (86.9) 556 (62.5) 922 (91.2)
Exposure to lubiprostone, median
(range), mcg/day
43.4 (0.8–204.0) 40.8 (2.0–129.6) 14.8 (0–50.5)
Pretreatment nausea, n (%)
Medical history of nausea 23 (2.1) 81 (9.1) 26 (2.6)
Prior treatment for nausea 7 (0.6) 22 (2.5) 7 (0.7)
Treatment-emergent nausea, n (%)
Crude incidence 346 (31.1) 124 (13.9) 115 (11.4)
Milda 184 (16.5) 71 (8.0) 63 (6.2)
Moderatea 123 (11.1) 44 (4.9) 43 (4.3)
Severea 39 (3.5) 9 (1.0) 9 (0.9)
Leading to discontinuation 97 (8.7) 19 (2.1) 13 (1.3)
BID twice daily, CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, OIC opioid-induced constipation
* P\ 0.001, Fisher’s exact test
 P\ 0.01, Fisher’s exact test
§ P\ 0.05, Fisher’s exact test
a Maximum reported severity for each patient
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in patients who received lubiprostone 24 mcg BID com-
pared with placebo in the CIC and OIC studies. On the
other hand, patients who received lubiprostone 8 mcg BID
had similar rates of discontinuation to placebo (Table 2). In
the CIC and IBS-C studies, no AEs of nausea met the
criteria to be considered as serious events (e.g., hospital-
ization). In the OIC studies, one patient treated with
lubiprostone experienced a serious AE of nausea; however,
this event was considered unrelated to study medication by
the study investigator.
In patients who reported severe nausea, 40–80% of
patients in each group had a history of medical conditions
predisposing them to nausea, though few had a medical
history of preexisting nausea (Table 3). Discontinuations
due to severe nausea were more common in the longer ‘‘all
trials’’ analysis of lubiprostone than in the shorter RCTs.
Patients Reporting a Single Nausea Event
or Persistent Nausea
Among lubiprostone-treated patients in the ‘‘all trials’’
populations who reported any AE of nausea (CIC [24 mcg
BID], n = 346; OIC [24 mcg BID], n = 124; IBS-C
[(8 mcg BID], n = 115), 83.5–88.7% reported only one
nausea event (Fig. 1a–c). More than 70% (70.7–73.8%) of
patients reporting a single event of nausea who did not
have a dose adjustment completed the full treatment per-
iod. Across the three indications, 8.3–17.7% of patients
who reported a single nausea event required lubiprostone
dose reduction to once daily or a temporary interruption of
lubiprostone treatment, which allowed the majority of these
patients to complete the full treatment period. Among
patients who reported C1 event of nausea (CIC, n = 69;
OIC, n = 18; IBS-C, n = 10), 55% with CIC, 78% with
OIC, and 100% with IBS-C remained in the study.
Temporal Pattern of Nausea
In the ‘‘all trials’’ population, 64.3% of overall nausea
events (393/611) occurred during the first 5 days of treat-
ment with lubiprostone (CIC, 77.2% [267/346]; OIC,
45.2% [56/124]; IBS-C, 49.6% [70/141]). In RCTs, the
median (range) for the first report of nausea was 2 (1–27), 5
(1–84), and 3 (1–90) days for the CIC, OIC, and IBS-C
studies, respectively (Fig. 2). Median values for the first
report of nausea in the long-term extension studies ranged
from 2 to 8.5 days.
Table 3 Medical history of nausea, history of medical conditions predisposing to nausea, and discontinuations due to nausea in patients who
reported severe nausea
Patients, n CIC OIC IBS-C
Placebo Lubiprostone 24 mcg
BID
Placebo Lubiprostone 24 mcg
BID
Placebo Lubiprostone 8 mcg
BID
n = 0 n = 5 n = 7 n = 7 n = 1 n = 5
Randomized controlled trials
Medical history of nausea NA 0 3 1 0 1
History of predisposing
conditionsa
NA 2 5 5 0 4
Discontinuation due to nausea NA 1 0 2 1 1
CIC OIC IBS-C
Lubiprostone 24 mcg BID Lubiprostone 24 mcg BID Lubiprostone 8 mcg BID
n = 39 n = 9 n = 9
All trials
Medical history of nausea 2 1 1
History of predisposing conditionsa 21 7 6
Discontinuation due to nausea 20 2 1
BID twice daily, CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, NA not applicable, OIC opioid-induced
constipation
a The following preferred terms were used: alcoholism, anaphylactic reaction, anorexia nervosa, appendicitis, vertigo positional, bulimia
nervosa, chemotherapy, cholecystitis, concussion, Crohn’s disease, cyclic vomiting syndrome, depression, diabetic ketoacidosis, dizziness, otitis
media, food poisoning, gastroesophageal reflux disease, impaired gastric emptying, general anesthesia, generalized anxiety disorder, myocardial
infarction, cardiac failure, hepatitis, pyrexia, hydrocephalus, hyperparathyroidism, hyperthyroidism, hypoparathyroidism, intestinal ischemia,
intestinal obstruction, intracranial hematoma, intussusception, irritable bowel syndrome, hepatic cancer, hepatic failure, Meniere’s disease,
meningitis, migraine, milk allergy, vomiting in pregnancy, pancreatic carcinoma, pancreatitis, peptic ulcer, benign intracranial hypertension,
pyloric stenosis, radiotherapy, rotavirus infection, pain, craniocerebral injury, vestibular neuronitis, or gastroenteritis viral
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Sex, Age, and Body Mass Index as Predictors
of Nausea
In the CIC, OIC, and IBS-C RCTs, comparisons between
patients who received lubiprostone or placebo found that
nausea rates were not significantly different between
women or men, or for those aged\65 or C65 years of age
or with body mass index (BMI)\25 or C25 (all P values
[0.394; Table 4). Rates of severe nausea were low overall.
Rates of nausea by sex, age, and BMI were also analyzed
within the group of patients in RCTs who received
lubiprostone treatment. In patients with CIC who received
lubiprostone, a significantly higher rate of nausea was
observed in women compared with men (P = 0.007), and
in patients aged\65 versus C65 years of age (P = 0.028)
(Table 4). There were no significant differences in the rates
of severe nausea in any of these subgroups. In patients with
OIC who received lubiprostone, there were no significant
differences in the rates of nausea by sex, age group, or
BMI, although there was a significantly higher rate
(P = 0.050) of severe nausea in women compared with
men (Table 4). In patients with IBS-C who received
lubiprostone, the rates of nausea (P = 0.0140) and severe
nausea (P = 0.0160) were significantly higher in patients
with BMI \25 compared with those with BMI C25
(Table 4).
Discussion
The pooled (‘‘all trials’’) analyses indicated that most
patients experienced no nausea during treatment with
lubiprostone. When nausea did occur, it was usually a
single event, and the typical onset was within the first
5 days of treatment. The majority of nausea AEs were mild
or moderate in severity and did not result in discontinuation
of treatment. Although the rates of severe nausea were low,
a higher rate of severe nausea was observed in patients with
IBS-C with a BMI \25 and in women with OIC. Fur-
thermore, nausea may be more common in women
Fig. 1 Treatment continuation among lubiprostone-treated patients who reported only one AE of nausea in the a chronic idiopathic constipation,
b opioid-induced constipation, and c irritable bowel syndrome with constipation studies. AE adverse event
Fig. 2 Cumulative incidence of events of nausea in lubiprostone-
treated patients in randomized controlled trials. The solid line denotes
CIC, the dashed line denotes OIC, and the dash-dotted line denotes
IBS-C. CIC chronic idiopathic constipation, IBS-C irritable bowel
syndrome with constipation, OIC opioid-induced constipation
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Table 4 Nausea incidence by sex, age group, and body mass index
CIC OIC IBS-C
Placebo Lubiprostone 24
mcg BID
P value* Placebo Lubiprostone 24
mcg BID
P value* Placebo Lubiprostone 8
mcg BID
P value*
Randomized controlled trials
Patients with
nausea, n
15 70 42 89 28 91
Sex, n (%)
Male 0 2 (2.9) 0.007 14
(33.3)
31 (34.8) 0.639 2 (7.1) 5 (5.5) 0.250
Female 15
(100)
68 (97.1) 28
(66.7)
58 (65.2) 26
(92.9)
86 (94.5)
Age group, n (%)
\65 years 14
(93.3)
68 (97.1) 0.028 37
(88.1)
84 (94.4) 0.821 26
(92.9)
82 (90.1) 0.292
C65 years 1 (6.7) 2 (2.9) 5 (11.9) 5 (5.6) 2 (7.1) 9 (9.9)
BMI
\25 10
(66.7)
37 (52.9) 0.117 10
(23.8)
23 (25.8) 0.501 13
(46.4)
51 (56.0) 0.014
C25 6 (33.3) 33 (47.1) 32
(76.2)
66 (74.2) 15
(53.6)
40 (44.0)
Patients with
severe nausea, n
0 5 7 7 1 5
Sex, n (%)
Male 0 0 1.000 4 (57.1) 0 0.050 0 1 (20.0) 0.377
Female 0 5 (100) 3 (42.9) 7 (100) 1 (100) 5 (80.0)
Age group, n (%)
\65 years 0 5 (100) 1.0000 6 (85.7) 6 (85.7) 0.390 1 (100) 5 (100) 1.0000
C65 years 0 0 1 (14.3) 1 (14.3) 0 0
BMI
\25 0 4 (80.0) 0.1760 1 (14.3) 2 (28.6) 0.665 0 5 (100) 0.0160
C25 0 1 (20.0) 6 (85.7) 5 (71.4) 1 (100) 0
CIC OIC IBS-C
Lubiprostone 24 mcg BID Lubiprostone 24 mcg BID Lubiprostone 8 mcg BID
All trials
Patients with nausea, n 346 124 115
Sex, n (%)
Male 12 (3.5) 44 (35.5) 6 (5.12)
Female 334 (96.5) 80 (64.5) 109 (94.8)
Age group, n (%)
\65 years 311 (89.9) 117 (94.4) 102 (88.7)
C65 years 35 (10.1) 7 (5.6) 13 (11.3)
BMI
\25 177 (51.2) 33 (26.6) 65 (56.5)
C25 169 (48.8) 91 (73.4) 50 (43.5)
Patients with severe nausea, n 39 9 9
Sex, n (%)
Male 1 (2.6) 2 (22.2) 1 (11.1)
Female 38 (97.4) 7 (77.8) 8 (88.9)
Age group, n (%)
\65 years 34 (87.2) 8 (88.9) 8 (88.9)
Dig Dis Sci (2017) 62:3568–3578 3575
123
compared with men as well as in younger versus older
adults at the higher dose (24 mcg BID).
Our data cannot definitively support or refute a dose–
response relationship with the incidence of treatment-
emergent nausea associated with lubiprostone. The higher
incidence of nausea with lubiprostone in patients with CIC,
compared with patients with IBS-C, would seem consistent
with the threefold difference in dose (24 vs 8 mcg BID,
respectively).The incidence of nausea in patients with OIC
who received lubiprostone 24 mcg BID was lower than the
incidence in patients with CIC at the same dose and closer
to the incidence in patients with IBS-C, who received the
lower dose. Arguably, the CIC and IBS-C patient popula-
tions have more overlap in terms of the clinical charac-
teristics and pathophysiology than does the OIC patient
population where the pathogenesis of constipation is more
clearly defined. No dose-dependent relationship between
lubiprostone dose and nausea was observed in a double-
blind, 3-week study with placebo or lubiprostone at total
doses of 24, 48, and 72 mcg/day in patients with CIC [5].
The percentage of lubiprostone-treated patients report-
ing nausea was higher in the CIC study population than in
the other two study populations. Comparing nausea rates
across the different indications may not be warranted
because of differences in patient characteristics, particu-
larly when considering patients with OIC versus those with
CIC or IBS-C. For example, the prevalence of baseline
(pretreatment) nausea was considerably greater in patients
with OIC compared with patients with CIC and IBS-C. It is
also possible that patients with OIC may have been less
sensitive to the occurrence of nausea caused by lubipros-
tone because the use of opioid agonists [19] is itself often
associated with nausea.
While this study did not explore the relationship
between efficacy of lubiprostone and adverse effects,
independent pooled analyses of randomized controlled
trials have been conducted for CIC, OIC, and IBS-C
[20–22]. These pooled analyses supported the beneficial
effects of lubiprostone across efficacy endpoints assessed.
Further, in each of these pooled analyses, the percentage of
patients discontinuing treatment due to lack of efficacy was
lower than that due to AEs. Importantly, nausea was not
responsible for a large number of discontinuations, and the
rates of nausea tended to decrease over the course of the
study.
The higher prevalence of nausea in young women
treated with lubiprostone in RCTs is consistent with
observations across studies that show greater incidences of
constipation and gastrointestinal dyspeptic symptoms,
including delayed gastric emptying, as well as slowed
colon transit time, in females than in males [23–28].
Similarly, a higher incidence of constipation and dyspeptic
symptoms has been reported in younger versus elderly
adults as well as in women of childbearing potential
[23–25, 28, 29]. Given the reported effects of lubiprostone
on delaying gastric emptying time [3], it is possible that
this effect is exacerbated in women who already have
elevated constipation and gastrointestinal dyspeptic symp-
toms at baseline and may contribute to the increased rates
of nausea observed in younger females.
While this study focused on the incidence of nausea in
constipated patients, nausea rates were evaluated inde-
pendently of the other AEs associated with lubiprostone
treatment. In particular, dyspnea has been reported in 2.5
and 1.3% of lubiprostone-treated CIC and OIC patients,
respectively [30]. In clinical studies, several patients dis-
continued lubiprostone treatment because of AEs regard-
less of severity, and in several patients continuing
treatment, a recurrence of symptoms was observed [30].
Further, in the CIC and IBS-C trials, headache was among
the most common treatment-related AEs (C5%) leading to
study discontinuation [5–7]. Collectively, these findings
suggest that individual sensitivities of patients to lubipro-
stone and the potential interactions between AEs may have
had a substantial effect on the observed safety profile.
The mechanisms underlying lubiprostone-induced nau-
sea have not been identified. In addition to activation of
ClC-2 chloride channels and the resultant increase in
intestinal secretion, lubiprostone has other effects on gas-
trointestinal function [2]. In two studies conducted in
Table 4 continued
CIC OIC IBS-C
Lubiprostone 24 mcg BID Lubiprostone 24 mcg BID Lubiprostone 8 mcg BID
C65 years 5 (12.8) 1 (11.1) 1 (11.1)
BMI, n (%)
\25 23 (59.0) 2 (22.2) 7 (77.8)
C25 16 (41.0) 7 (77.8) 2 (22.2)
BID twice daily, BMI body mass index, CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, OIC opioid-
induced constipation
* P values for comparison of the differences of the incidence rate between the subgroups in patients treated with lubiprostone using the Fisher’s
exact test
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healthy adults, lubiprostone significantly delayed gastric
emptying and increased fasting gastric volume [3, 31].
These findings differ from what has been observed in
preclinical studies, which show accelerated gastric emp-
tying with lubiprostone treatment [32]. However, acceler-
ated gastric emptying was not observed at lower doses,
which are more comparable to those administered in the
clinical setting.
While delayed gastric emptying and increased fasting
gastric volume may play a role in mediating lubiprostone-
induced nausea, other factors such as increased intestinal
secretion and suppression of defecation may contribute to
this phenomenon. In patients with functional dyspepsia,
small intestinal distension has been associated with the
occurrence of nausea, suggesting that increased secretion in
the small intestine resulting in local distension may con-
tribute to nausea symptoms [33]. Further, it is well known
that suppression of defecation increases gastric emptying
time, which could induce nausea, as has been observed in
studies with healthy volunteers [34]. Therefore, patients
with defecation disorders might be more prone to experi-
encing nausea while taking lubiprostone.
In addition to perturbations in intestinal physiology and
defecation, the time of drug intake relative to food con-
sumption may also modify the side-effect profile of
lubiprostone. In the first CIC study (RTU0211SC9921),
lubiprostone was taken before a meal (Table 1), whereas in
all other studies, it was taken during a meal. Consistent
with the observation that less nausea has been observed
when lubiprostone is co-administered with food, the
aforementioned study conducted in healthy adults found
that increases in gastric volume did not occur when
lubiprostone was administered after a fully satiating meal
[3]. This observation is consistent with the US Food and
Drug Administration’s recommendation to take the medi-
cation with food and water [1].
One possible explanation for why patients with CIC
exhibited the highest incidence of nausea in the clinical
trials is that, unlike patients in the OIC and IBS-C studies,
no explicit instruction was given to take the treatment with
food. Since a detailed characterization of nausea was not a
specific objective of the pivotal studies, only limited data
on nausea were collected, thus limiting the scope of the
current analyses.
In conclusion, nausea was more common in patients
with CIC compared with OIC and IBS-C. In patients with
CIC, but not OIC or IBS-C, women were more likely than
men to report nausea. Most patients treated with lubipro-
stone in the pooled study analyses for CIC, OIC, and IBS-C
who reported nausea reported only a single incidence, and
most of those events were of mild to moderate severity. In
general, patients who experienced nausea were able to
complete the studies. Useful strategies for the management
of lubiprostone-induced nausea include emphasizing that
the medication should be taken with food and water (the
recommended dosing procedure), reducing the dose, or
temporarily withholding doses [1]. Treating physicians
may wish to be particularly vigilant by expectantly advis-
ing women (CIC and OIC), patients aged\65 (CIC), and
patients with a BMI \25 (IBS-C) for the potential of
nausea. Such an approach may be beneficial in helping
patients achieve successful therapy.
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